The multiplex assays market is segmented on the basis of product & services, type, technology, application, end user, and region. By product and service, the multiplex assays market is segmented into instruments, consumables, and software & services. In 2018, the consumables segment is expected to account for the largest share of the market; it is also the fastest-growing segment of the multiplex assays market. This can be attributed to the recurring purchase of assays and reagents for increasing research applications.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=61593314
On the basis of type, the global multiplex assays market is divided into protein multiplex assays, nucleic acid multiplex assays, and cell-based multiplex assays. In 2018, the protein multiplex assays segment is expected to grow at fastest CAGR in the global multiplex assays market. This high growth can be attributed to the increasing focus on proteomics studies for biomarker research and clinical diagnostics.
On the basis of technology, the global multiplex assays market is divided into flow cytometry, multiplex RT PCR, luminescence, fluorescence detection, and other technologies. In 2018, the flow cytometry segment is expected to grow at the highest CAGR in the global multiplex assays market. The high growth can be attributed to the wide applications of flow cytometry in detection & measurement of protein expression, RNA, cell health status (cell viability & toxicity), and characterization & identification of various cell types.
On the basis of application, the global multiplex assays market is divided into research & development and clinical diagnostics. In 2018, the clinical diagnostics segment is expected to grow at the highest CAGR in the global multiplex assays market. This high growth can be attributed to increasing disease prevalence and adoption of multiplex assays in diagnosis.
On the basis of end user, the global multiplex assays market is divided into pharmaceutical and biotechnology companies, hospitals & academic research institutes, reference laboratories, and other end users. In 2018, the pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR in the global multiplex assays market. This high growth can be attributed to the increased adoption of multiplex assays in drug discovery & development by pharmaceuticals and the growing focus of biotechnology companies on developing biosimilars and monoclonal antibodies.
The APAC market is projected to register the highest growth rate during the forecast period primarily due to its pharmaceutical market, which is growing at the fastest pace in the world, the availability of a large number of qualified researchers, and increasing prevalence of cancer and infectious diseases.
